Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Phenytoin for neuroprotection in patients with acute optic neuritis: a randomised, placebo-controlled, phase 2 trial.
QualiCOP: real-world effectiveness, tolerability, and quality of life in patients with relapsing-remitting multiple sclerosis treated with glatiramer acetate, treatment-naïve patients, and previously treated patients.
Transverse myelitis associated with heroin and cannabis abuse: a new issue from the past.
Vinpocetine inhibits oligodendroglial precursor cell differentiation.
Anti-phospholipid antibodies are associated with response to interferon-beta1a treatment in MS: results from a 3-year longitudinal study.
Long-term efficacy of B cell depletion therapy on lung and skin involvement in diffuse systemic sclerosis.
Safety and Tolerability Study of MEDI-551, a B-cell Depleting Agent, to Treat Relapsing Forms of Multiple Sclerosis
A Randomized Placebo-Controlled, Crossover-Design Study of the Effects of Low Dose Naltrexone
Don't stress about it!: Is stress management a disease-modifying therapy for multiple sclerosis?
Bridging the Brain Disease Knowledge Gap Through Computational Modeling and Systems Biology
High risk of MS in Iranian immigrants in Gothenburg, Sweden.
Minocycline in rheumatoid arthritis. A 48-week, double-blind, placebo-controlled trial. MIRA Trial Group.
Biologics at Novartis
Incidental MRI anomalies suggestive of multiple sclerosis: the radiologically isolated syndrome.
Systemic inflammation in progressive multiple sclerosis involves follicular T-helper, th17- and activated B-cells and correlates with progression.
The AusD Study: A Population-based Study of the Determinants of Serum 25-Hydroxyvitamin D Concentration Across a Broad Latitude Range.
Correlates of Executive Functions in Multiple Sclerosis Based on Structural and Functional MR Imaging: Insights from a Multicenter Study.
Delta 9-tetrahydrocannabinol: a novel treatment for experimental autoimmune encephalomyelitis.
A Study to Evaluate the Long-term Safety, Tolerability and Effect of Daily Oral Laquinimod 0.6 mg on Disease Course in Subjects With Relapsing Multiple Sclerosis
ATX-MS-1467 - Positive Immunological data in Multiple Sclerosis: Final Phase I/IIa data shows safety and tolerability, plus efficacy
Mesenchymal stem cells expressing vasoactive intestinal peptide ameliorate symptoms in a model of chronic multiple sclerosis.
The contemporary spectrum of multiple sclerosis misdiagnosis: A multicenter study.
Magnetic Resonance Spectroscopy Markers of Disease Progression in Multiple Sclerosis.
Cytokines and Disability in Interferon-β-1b Treated and Untreated Women with Multiple Sclerosis.
Evaluation of Dalfampridine Extended Release 5 and 10 mg in Multiple Sclerosis: A Randomized Controlled Trial.

Pages